Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients: A pilot trial

S. Mahabir, D. Coit, L. Liebes, M. S. Brady, J. J. Lewis, G. Roush, Marion Nestle, D. Fry, M. Berwick

Research output: Contribution to journalArticle

Abstract

We evaluated the effects of vitamin E (DL-α-tocopherol) on mutagen sensitivity levels in a randomized placebo-controlled pilot trial. In brief, a dietary supplement of 1000 mg/day vitamin E or a placebo was randomly administered for 3 months to melanoma outpatients clinically free of the disease. Plasma vitamin E and mutagen sensitivity levels were measured at baseline and at the end of the trial after 3 months. At baseline, we found no significant differences in plasma vitamin E and mutagen sensitivity levels between the two groups. We also measured dietary intake at baseline and found dietary vitamin E to be a poor predictor of plasma levels of vitamin E. After 3 months of supplementation, we found that plasma levels of α-tocopherol increased significantly (P= 0.0005) in the vitamin E compared to the placebo group. We also found a non-significant, but consistent decrease in plasma γ-tocopherol concentrations in the vitamin E supplemented compared to the placebo group. We did not find any significant difference between the vitamin E and placebo groups in mutagen sensitivity levels either at baseline or after 3 months of supplementation. We conclude that short term vitamin E supplementation, although it causes increased blood levels of α-tocopherol, does not provide protection against bleomycin-induced chromosome damage.

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalMelanoma Research
Volume12
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Tocopherols
Mutagens
Dietary Supplements
Vitamin E
Melanoma
Randomized Controlled Trials
Placebos
Bleomycin
Outpatients
Chromosomes

Keywords

  • Melanoma
  • Mutagen sensitivity
  • Vitamin E

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this

Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients : A pilot trial. / Mahabir, S.; Coit, D.; Liebes, L.; Brady, M. S.; Lewis, J. J.; Roush, G.; Nestle, Marion; Fry, D.; Berwick, M.

In: Melanoma Research, Vol. 12, No. 1, 2002, p. 83-90.

Research output: Contribution to journalArticle

Mahabir, S. ; Coit, D. ; Liebes, L. ; Brady, M. S. ; Lewis, J. J. ; Roush, G. ; Nestle, Marion ; Fry, D. ; Berwick, M. / Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients : A pilot trial. In: Melanoma Research. 2002 ; Vol. 12, No. 1. pp. 83-90.
@article{308bb7e519fa48a3a4872fcf8370bb74,
title = "Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients: A pilot trial",
abstract = "We evaluated the effects of vitamin E (DL-α-tocopherol) on mutagen sensitivity levels in a randomized placebo-controlled pilot trial. In brief, a dietary supplement of 1000 mg/day vitamin E or a placebo was randomly administered for 3 months to melanoma outpatients clinically free of the disease. Plasma vitamin E and mutagen sensitivity levels were measured at baseline and at the end of the trial after 3 months. At baseline, we found no significant differences in plasma vitamin E and mutagen sensitivity levels between the two groups. We also measured dietary intake at baseline and found dietary vitamin E to be a poor predictor of plasma levels of vitamin E. After 3 months of supplementation, we found that plasma levels of α-tocopherol increased significantly (P= 0.0005) in the vitamin E compared to the placebo group. We also found a non-significant, but consistent decrease in plasma γ-tocopherol concentrations in the vitamin E supplemented compared to the placebo group. We did not find any significant difference between the vitamin E and placebo groups in mutagen sensitivity levels either at baseline or after 3 months of supplementation. We conclude that short term vitamin E supplementation, although it causes increased blood levels of α-tocopherol, does not provide protection against bleomycin-induced chromosome damage.",
keywords = "Melanoma, Mutagen sensitivity, Vitamin E",
author = "S. Mahabir and D. Coit and L. Liebes and Brady, {M. S.} and Lewis, {J. J.} and G. Roush and Marion Nestle and D. Fry and M. Berwick",
year = "2002",
doi = "10.1097/00008390-200202000-00012",
language = "English (US)",
volume = "12",
pages = "83--90",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients

T2 - A pilot trial

AU - Mahabir, S.

AU - Coit, D.

AU - Liebes, L.

AU - Brady, M. S.

AU - Lewis, J. J.

AU - Roush, G.

AU - Nestle, Marion

AU - Fry, D.

AU - Berwick, M.

PY - 2002

Y1 - 2002

N2 - We evaluated the effects of vitamin E (DL-α-tocopherol) on mutagen sensitivity levels in a randomized placebo-controlled pilot trial. In brief, a dietary supplement of 1000 mg/day vitamin E or a placebo was randomly administered for 3 months to melanoma outpatients clinically free of the disease. Plasma vitamin E and mutagen sensitivity levels were measured at baseline and at the end of the trial after 3 months. At baseline, we found no significant differences in plasma vitamin E and mutagen sensitivity levels between the two groups. We also measured dietary intake at baseline and found dietary vitamin E to be a poor predictor of plasma levels of vitamin E. After 3 months of supplementation, we found that plasma levels of α-tocopherol increased significantly (P= 0.0005) in the vitamin E compared to the placebo group. We also found a non-significant, but consistent decrease in plasma γ-tocopherol concentrations in the vitamin E supplemented compared to the placebo group. We did not find any significant difference between the vitamin E and placebo groups in mutagen sensitivity levels either at baseline or after 3 months of supplementation. We conclude that short term vitamin E supplementation, although it causes increased blood levels of α-tocopherol, does not provide protection against bleomycin-induced chromosome damage.

AB - We evaluated the effects of vitamin E (DL-α-tocopherol) on mutagen sensitivity levels in a randomized placebo-controlled pilot trial. In brief, a dietary supplement of 1000 mg/day vitamin E or a placebo was randomly administered for 3 months to melanoma outpatients clinically free of the disease. Plasma vitamin E and mutagen sensitivity levels were measured at baseline and at the end of the trial after 3 months. At baseline, we found no significant differences in plasma vitamin E and mutagen sensitivity levels between the two groups. We also measured dietary intake at baseline and found dietary vitamin E to be a poor predictor of plasma levels of vitamin E. After 3 months of supplementation, we found that plasma levels of α-tocopherol increased significantly (P= 0.0005) in the vitamin E compared to the placebo group. We also found a non-significant, but consistent decrease in plasma γ-tocopherol concentrations in the vitamin E supplemented compared to the placebo group. We did not find any significant difference between the vitamin E and placebo groups in mutagen sensitivity levels either at baseline or after 3 months of supplementation. We conclude that short term vitamin E supplementation, although it causes increased blood levels of α-tocopherol, does not provide protection against bleomycin-induced chromosome damage.

KW - Melanoma

KW - Mutagen sensitivity

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=0036190992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036190992&partnerID=8YFLogxK

U2 - 10.1097/00008390-200202000-00012

DO - 10.1097/00008390-200202000-00012

M3 - Article

C2 - 11828262

AN - SCOPUS:0036190992

VL - 12

SP - 83

EP - 90

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -